The Role of Obstructive Sleep Apnea in the Acutely Decompensated Heart Failure

阻塞性睡眠呼吸暂停在急性失代偿性心力衰竭中的作用

基本信息

  • 批准号:
    7689265
  • 负责人:
  • 金额:
    $ 18.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-17 至 2012-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The prevalence of Sleep Disordered Breathing (SDB) in patients with stable heart failure exceeds 50%, and usually goes unrecognized and untreated. Obstructive Sleep Apnea (OSA) has strong etiological relationships with obesity, aging, hypertension and diabetes, all of which are causes of chronic heart failure. In a large population based study, OSA was an independent risk factor for developing heart failure. Obesity, and aging, both on the rise in the general population, are risk factors for both OSA and heart failure. Therefore, it is likely that OSA is playing a significant role in the progression of cardiac dysfunction in patients with cardiovascular disease, obesity, or aging. OSA, an established cause of hypertension, promotes poor outcomes of hypertension, Coronary Artery Disease (CAD), and atrial and ventricular arrhythmia, all of which are causes of Acutely Decompensated Heart Failure (ADHF). Therefore, OSA may particularly be implicated in the acute decompensation of heart failure, a condition often triggered by atrial fibrillation, CAD or hypertension. Our preliminary data confirm that 62% of patients hospitalized with ADHF have unrecognized OSA; an even higher prevalence than the current estimates in patients with stable heart failure. Episodes of obstructive apnea produce intermittent hypoxia, increased sympathetic activity, and large negative intra-thoracic pressure swings, all of which are devastating perturbations in patients with deteriorating cardiac function and may lead to decompensated heart failure. There is strong evidence that treatment of OSA with Continuous Positive Airway pressure (CPAP) reduces fatal and non-fatal cardiovascular events. Additionally, in patients with OSA and underlying heart failure, CPAP improves ejection fraction, sympathetic activity, and functional status. Despite these findings, systematic approaches to identifying and treating new cases of OSA among patients hospitalized for ADHF or even patients with stable heart failure are not part of current management guidelines. An evaluation of a systematic diagnostic and therapeutic strategy for OSA in patients hospitalized with ADHF has not been undertaken to date. This proposed research will evaluate the impact of an approach of expedited inpatient identification and treatment of OSA on within hospital and 3 month post-discharge cardiac and functional outcomes, through a randomized trial. Patients with ADHF will undergo an in-hospital sleep study. Among patients with ADHF who are newly diagnosed with OSA, one group (n=85) will receive immediate treatment for OSA during their hospitalization while the other randomized group (n=85) will receive the current standard of care including outpatient diagnosis with in-lab sleep study and outpatient initiation of CPAP. The effect of this approach on patients' adherence to CPAP will also be evaluated. PUBLIC HEALTH RELEVANCE: This proposed research will evaluate the impact of a systematic approach of inpatient identification and treatment of OSA in patients with Acutely Decompensated Heart Failure on within hospital and 3 month post-discharge cardiac and functional outcomes, through a randomized trial.
描述(由申请人提供):睡眠呼吸障碍(SDB)在稳定性心力衰竭患者中的患病率超过50%,通常无法识别和治疗。阻塞性睡眠呼吸暂停(OSA)与肥胖、衰老、高血压和糖尿病有很强的病因学关系,所有这些都是慢性心力衰竭的原因。在一项大规模人群研究中,OSA是发生心力衰竭的独立危险因素。肥胖和老龄化在普通人群中都在增加,是OSA和心力衰竭的危险因素。因此,阻塞性睡眠呼吸暂停很可能在心血管疾病、肥胖或衰老患者的心功能障碍进展中发挥重要作用。OSA是高血压的一个既定原因,促进高血压、冠状动脉疾病(CAD)和室性心律失常的不良结局,所有这些都是急性失代偿性心力衰竭(ADHF)的原因。因此,OSA可能特别与心力衰竭的急性失代偿有关,心力衰竭是一种经常由心房颤动、CAD或高血压引发的疾病。我们的初步数据证实,62%的ADHF住院患者患有未被识别的OSA;这一患病率甚至高于目前对稳定性心力衰竭患者的估计。阻塞性呼吸暂停的发作会产生间歇性缺氧、交感神经活动增加和大的负胸内压波动,所有这些都是心脏功能恶化患者的破坏性扰动,并可能导致失代偿性心力衰竭。有强有力的证据表明,持续气道正压通气(CPAP)治疗OSA可减少致命和非致命的心血管事件。此外,在患有OSA和潜在心力衰竭的患者中,CPAP改善射血分数、交感神经活性和功能状态。尽管有这些发现,但在因ADHF住院的患者甚至稳定性心力衰竭患者中识别和治疗OSA新发病例的系统方法并不是当前管理指南的一部分。迄今为止,尚未对ADHF住院患者的OSA系统诊断和治疗策略进行评价。这项拟议的研究将通过随机试验评估快速住院识别和治疗阻塞性睡眠呼吸暂停综合症的方法对院内和出院后3个月心脏和功能结局的影响。ADHF患者将接受院内睡眠研究。在新诊断为OSA的ADHF患者中,一组(n=85)将在住院期间立即接受OSA治疗,而另一组(n=85)将接受当前标准治疗,包括门诊诊断和实验室内睡眠研究以及门诊开始CPAP。还将评估这种方法对患者坚持CPAP的影响。 公共卫生关系:这项拟议的研究将通过一项随机试验,评价急性失代偿性心力衰竭患者中OSA住院识别和治疗的系统方法对院内和出院后3个月心脏和功能结局的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rami N Khayat其他文献

Rami N Khayat的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rami N Khayat', 18)}}的其他基金

The Microcirculation in OSA
OSA 的微循环
  • 批准号:
    8032824
  • 财政年份:
    2011
  • 资助金额:
    $ 18.26万
  • 项目类别:
The Microcirculation in OSA
OSA 的微循环
  • 批准号:
    8233917
  • 财政年份:
    2011
  • 资助金额:
    $ 18.26万
  • 项目类别:
The Role of Obstructive Sleep Apnea in the Acutely Decompensated Heart Failure
阻塞性睡眠呼吸暂停在急性失代偿性心力衰竭中的作用
  • 批准号:
    7824337
  • 财政年份:
    2009
  • 资助金额:
    $ 18.26万
  • 项目类别:
The Role of Obstructive Sleep Apnea in the Acutely Decompensated Heart Failure
阻塞性睡眠呼吸暂停在急性失代偿性心力衰竭中的作用
  • 批准号:
    7531637
  • 财政年份:
    2008
  • 资助金额:
    $ 18.26万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了